Tenax Therapeutics Posts $17.8M Q2 Loss, Extends Cash Runway to Q2 2028, and Nears Phase 3 Topline Readout
TENX has more than doubled off its 52-week low of $5.78 on elevated volume (1.8× avg).
Summary
Tenax Therapeutics reported a $17.8M net loss for Q2 2026, held $118M in cash, and extended its runway to Q2 2028. Topline Phase 3 LEVEL trial data are expected in August 2026.
Key Events · Earnings and Guidance · TENX
-
Q2 2026 Net Loss Widens
The net loss reached $17.8 million, up from $10.9 million in Q2 2025, as R&D expenses climbed to support the Phase 3 LEVEL and LEVEL-2 trials.
-
Cash Runway Extended to Q2 2028
Cash and equivalents stood at $118.0 million on June 30, 2026, after $13.4 million in warrant exercises during the quarter, funding operations through Q2 2028.
-
Phase 3 LEVEL Topline Data Imminent
Topline results from the Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF are due in August 2026, with a late-breaking presentation slated for the ESC Congress on August 28-31.
-
LEVEL-2 Enrollment on Track
Enrollment continues in the second global Phase 3 trial, LEVEL-2, and is expected to complete by the end of 2027.
Analysis · TENX · Life Sciences
A wider Q2 net loss of $17.8 million reflects the ramp in R&D spending behind two Phase 3 trials of oral levosimendan. The quarter ended with $118 million in cash, strengthened by $13.4 million from warrant exercises, which pushes the runway into Q2 2028. The investment thesis now hinges on a binary catalyst: topline data from the Phase 3 LEVEL trial, expected in August 2026 and set for a late-breaking presentation at the ESC Congress at month-end.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1457 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $15.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.5M. The 52-week trading range was $5.78 to $19.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.